A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases

NCT07249892 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Solid Tumors

Interventions

DRUG: BPR-6023021 for injection

Sponsor

Chengdu Syncor Pharmaceutical Co., Ltd.

Collaborators

[object Object]